Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s

Drug Metabolism and Disposition

Volumn 29, Issue 1, 2001, Pages 30-35

  Bapiro, Tashinga E ^a   Egnell, Ann Charlotte ^b   Hasler, Julia A ^a   Masimirembwa, Collen M ^b  

^a UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIPARASITIC AGENT; ARTEMISIN; COUMARIN; CYCLOGUANIL; CYTOCHROME P450 ISOENZYME; DEETHYLAMODIAQUINE; DICLOFENAC; DIHYDROARTEMISININ; NICLOSAMIDE; PHENAZONE; PRIMAQUINE; PROGUANIL; THEOPHYLLINE; TIABENDAZOLE;

ARTICLE; CORRELATION FUNCTION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SUBSTRATE; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER MICROSOME; PRIORITY JOURNAL;

ANTIPROTOZOAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; SPECTROMETRY, FLUORESCENCE;

EID: 0035155095     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Effect of chloroquine and primaquine on antipyrine metabolism
2. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
3. Making malaria-treatment policy in the face of drug resistance
4. Characterisation of the inhibition of 1A2 by furafylline
5. Assays for cytochrome P450 inhibition
6. Current status of artemisinin and its derivatives as antimalarial drugs
7. Clinical pharmacokinetics of anthelmintic drugs
8. Overview of experimental approaches for study of drug metabolism and drug-drug interactions
9. Pharmacokinetics of drug interactions
10. CYP3A4 drug interactions: Correlation of 10 in vitro probe substrates
11. The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man
12. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2
13. Incidence of adverse drug reactions in hospitalised patients: A meta-analysis of prospective studies
14. Theophylline-thiabendazole drug interaction
15. DNA adduct formation in liver and kidney of male Syrian hamsters treated with estrogen and/or alpha-naphthoflavone
16. Inhibition and induction of cytochrome P450 and the clinical implications
17. Genetic polymorphism of drug metabolising enzymes in African populations: Implications for the use of neuroleptics and antidepressants
18. Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6
19. Heterologous expression and kinetic characterisation of human cytochrome P450: Validation of a pharmaceutical tool for drug metabolism research
20. Pharmacokinetic and pharmacodynamic interactions of mefloquine and dihydroartemisinin
21. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity
22. Application of human liver microsomes in metabolism-based drug-drug interactions: In vitro-in vivo correlations and the Abbott Laboratories experience
23. Antiparasitic agents
24. Theophylline and antiparasitic drug interactions. A case report and study of the influence of theophylline pharmacokinetics in adults
25. Primaquine as prophylaxis for malaria for nonimmune travellers: A comparison with mefloquine and doxycycline
26. Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine
27. Withdrawal of posicor from market
28. Theophylline and related xanthine drug interactions
29. Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity
30. Theophylline metabolism in human liver microsomes: Inhibition studies
31. CYF2C9 is a principal low-affinity phenacetin O-deethylase: Flovoxamine is not a specific CYP1A2 inhibitor
32. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction
33. Antimalarial drug resistance and combination chemotherapy